AFM13 is a tetravalent, CD16A/CD30 bispecific Innate Cell Engager that binds CD30 on PTCL cells and CD16A on innate effector cells, thereby redirecting and enhancing the innate immune response to the tumor cells. Here, FCGR3A is linked to neoplasm.